Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

The pharmaceutical giant claims that Gutierrez Co. failed to properly design and build its manufacturing facility in Marlborough, Massachusetts.

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and Drug Administration’s top vaccine official has resigned. Watch these key ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US ...

U.S. stock futures point lower as investors await tomorrow's announcement on reciprocal tariffs, and OpenAI announces a $40 ...

In this article, we are going to look at where Moderna, Inc. (NASDAQ:MRNA) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market conditions ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...